15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Castle Biosciences Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $40.00 to $52.00, so the covering firms are broadly aligned. The average target of $43.67 sits 83% above the current $23.90. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.30 next quarter toward $-0.96 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Castle Biosciences Inc.
As of Jul, 6 of 6 firms rate CSTL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CSTL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.30
Range $-0.41 – $-0.14 · 9 analysts · +1406% YoY
Next period, 9 analysts expect Castle Biosciences Inc to earn $-0.30 a share (range $-0.41 – $-0.14), versus $-0.02 a year earlier. Full-year consensus is $-1.42, growing to $-0.96 the year after.
REVENUE · NEXT QUARTER
$90.4M
Range $89.3M – $91.5M · 9 analysts · +9% YoY
Revenue is expected to reach $90.4M (range $89.3M – $91.5M), +8.8% year-over-year. Full-year consensus is $352.3M, rising to $392.9M next year.
Top analysts covering Castle Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CSTL.
#1
KM
Kyle Mikson
Canaccord Genuity · Rank #192
Buy
$40.00+67.4% to target
Overall win rate
35%
+ Follow
#2
SJ
Sung Ji Nam
Scotiabank · Rank #196
Buy
$40.00+67.4% to target
Overall win rate
45%
+ Follow
#3
Paul Knight
Keybanc · Rank #296
Buy
$50.00+109.2% to target
Overall win rate
32%
+ Follow
#4
CR
Catherine Ramsey
Baird
Buy
$43.00+79.9% to target
Coverage
—
+ Follow
#5
TF
Thomas Flaten
Lake Street
Buy
$52.00+117.6% to target
Coverage
—
+ Follow
CSTL stock forecast FAQ
What is CSTL's average 12-month price target?+
The 6 analysts with a live target average $43.67 for Castle Biosciences Inc over the next 12 months, ranging from a $52.00 high to a $40.00 low.
Is CSTL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CSTL?+
The Street-high target is $52.00 (Lake Street), and the Street-low is $40.00 (Roth Capital). The average of all 6 active targets is $43.67.
How many Wall Street analysts cover CSTL?+
6 analysts have an active rating on Castle Biosciences Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CSTL?+
Among analysts who currently cover CSTL, Kyle Mikson of Canaccord Genuity has the strongest overall Quantellect track record (Rank #192). Their current call is Buy with a $40.00 target.
What is Castle Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.30 per share (range $-0.41 – $-0.14) across 9 analysts. Full-year EPS is projected at $-1.42, rising to $-0.96 the following year.
How much revenue is Castle Biosciences Inc expected to report next quarter?+
Consensus revenue is $90.4M (range $89.3M – $91.5M). Full-year revenue is projected at $352.3M, growing to $392.9M next year.
Have analysts been upgrading or downgrading CSTL lately?+
As of Jul, 6 of 6 firms rate CSTL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CSTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
